Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 21;23(9):101487.
doi: 10.1016/j.isci.2020.101487. Online ahead of print.

Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery

Ronald L Davis  1
Affiliations
Review

Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery

Ronald L Davis. iScience. .

Abstract

Two opposing viewpoints are held regarding the need for understanding a drug's molecular target and mechanism of action. One extreme viewpoint is that it is unnecessary, because, after all, there are many beneficial drugs in use for which the target and mechanism of action remain unknown. A second extreme viewpoint is that target identification and mechanism of action should be elucidated very early in the drug discovery process due to the tangible benefits provided by this knowledge. I offer an intermediate perspective that considers the complexity of the disease of interest, the existence of a standard-of-care treatment, and the resources available to the investigator.

Keywords: Health Sciences; Pharmaceutical Science.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Paths for Preclinical Drug Discovery
See this image and copyright information in PMC

References

    1. Aisen P.S. Editorial: failure after failure. What next in AD drug development? J. Prev. Alzheimers Dis. 2019;6:150. - PubMed
    1. Aulner N., Danckaert A., Ihm J., Shum D., Shorte S.L. Next-generation phenotypic screening in early drug discovery for infectious diseases. Trends Parasitol. 2019;35:559–570. - PubMed
    1. Barginear M.F., John V., Budman D.R. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol. Med. 2013;18:1473–1479. - PMC - PubMed
    1. Brown D.G., Wobst H.J. Opportunities and challenges in phenotypic screening for neurodegenerative disease research. J. Med. Chem. 2020;63:1823–1840. - PubMed
    1. Clatworthy A.E., Romano K.P., Hung D.T. Whole-organism phenotypic screening for anti-infectives promoting host health. Nat. Chem. Biol. 2018;14:331–341. - PMC - PubMed

LinkOut - more resources